Page last updated: 2024-09-03

adenosine amine congener and enkephalin, leucine

adenosine amine congener has been researched along with enkephalin, leucine in 1 studies

Compound Research Comparison

Studies
(adenosine amine congener)
Trials
(adenosine amine congener)
Recent Studies (post-2010)
(adenosine amine congener)
Studies
(enkephalin, leucine)
Trials
(enkephalin, leucine)
Recent Studies (post-2010) (enkephalin, leucine)
290511,52480754

Protein Interaction Comparison

ProteinTaxonomyadenosine amine congener (IC50)enkephalin, leucine (IC50)
Delta-type opioid receptorMus musculus (house mouse)0.0142
Kappa-type opioid receptorMus musculus (house mouse)0.0417
Mu-type opioid receptorHomo sapiens (human)9.5
Mu-type opioid receptorMus musculus (house mouse)0.0308
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.246

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bantubungi, K; Blum, D; d'Alcantara, P; Galas, MC; Gall, D; Schiffmann, SN1

Other Studies

1 other study(ies) available for adenosine amine congener and enkephalin, leucine

ArticleYear
The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Oct-15, Volume: 22, Issue:20

    Topics: Adenosine; Animals; Behavior, Animal; Binding, Competitive; Body Weight; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dystonia; Enkephalins; Hindlimb; Huntington Disease; In Vitro Techniques; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Propionates; Purinergic P1 Receptor Agonists; Rats; Rats, Inbred Lew; Reproducibility of Results; RNA, Messenger; Succinate Dehydrogenase; Synaptic Transmission; Treatment Outcome

2002